NICHD research on muscular dystrophy (MD) encompasses a wide variety of topics, including basic, translational, and clinical studies. The NICHD and other NIH institutes are working to develop new therapies for Duchenne and Becker MD. NICHD-funded studies also aim to identify the underlying molecular and cellular pathology of facioscapulohumeral (pronounced fas-see-oh-skap-you-low-HEW-mur-l) muscular dystrophy (FSHD). Scientists are currently establishing a biomarker database for FSHD research, which collects information gathered from muscle tissue and cell repositories. Through the National Center for Medical Rehabilitation Research, NICHD research encompasses the impacts of musculoskeletal disorders on motor and sensory functions, bone loss, obesity, muscle atrophy, pressure ulcers, bladder and bowel disorders, and pain, in addition to psychological and psychosocial conditions and limitations in mobility.